“…The current evidence on the safety and efficacy of drug transition from one PAH-specific therapy to another includes the transition involving prostacyclin and its analogs ( Hoeper et al, 2002 ; Gomberg-Maitland et al, 2005 ; Ewert et al, 2007 ; Rubenfire et al, 2007 ; Sitbon et al, 2007 ; Shlobin et al, 2012 ; Bourge et al, 2013 ; Minai et al, 2013 ; Shapiro et al, 2013 ; Tamura et al, 2013 ; Frantz et al, 2014 ; Frantz et al, 2015 ; Fukumoto et al, 2015 ; Lichtblau et al, 2015 ; Chakinala et al, 2017 ; Frost et al, 2019 ) or PDE-5i ( Tay et al, 2008 ; Verlinden et al, 2020 ), but minimal data on the switch between ERA. A study reported that the switch from bosentan or sitaxentan to ambrisentan in patients with liver abnormalities is safe and can offer clinical improvement ( McGoon et al, 2009 ).…”